Application and pharmacological mechanism of methotrexate in rheumatoid arthritis.

[1]  Chengjie Deng,et al.  Recent advances on signaling pathways and their inhibitors in rheumatoid arthritis. , 2021, Clinical immunology.

[2]  G. Nolan,et al.  Diminished cytokine-induced Jak/STAT signaling is associated with rheumatoid arthritis and disease activity , 2021, PloS one.

[3]  Jie Li,et al.  Nuclear factor‐κB in rheumatoid arthritis , 2020, International journal of rheumatic diseases.

[4]  S. Ceruti,et al.  Adenosine Signaling in Autoimmune Disorders , 2020, Pharmaceuticals.

[5]  Xiaofeng Li,et al.  Low-dose Interleukin-2: Biology and therapeutic prospects in rheumatoid arthritis. , 2020, Autoimmunity reviews.

[6]  A. Mócsai,et al.  Osteoclast Signal Transduction During Bone Metastasis Formation , 2020, Frontiers in Cell and Developmental Biology.

[7]  M. Pešić,et al.  Analysis of association of ADORA2A and ADORA3 polymorphisms genotypes/haplotypes with efficacy and toxicity of methotrexate in patients with Rheumatoid arthritis , 2020, The Pharmacogenomics Journal.

[8]  T. Popkova,et al.  Regulatory T cells in patients with early untreated rheumatoid arthritis: Phenotypic changes in the course of methotrexate treatment. , 2020, Biochimie.

[9]  M. Zeidler,et al.  How does methotrexate work? , 2020, Biochemical Society transactions.

[10]  T. Horiuchi,et al.  Usefulness of daily folic acid supplementation during methotrexate treatment of Japanese patients with rheumatoid arthritis , 2020, Modern rheumatology.

[11]  T. Aune,et al.  Methotrexate and its mechanisms of action in inflammatory arthritis , 2020, Nature Reviews Rheumatology.

[12]  Xiaoning Zhang,et al.  Reactive oxygen species, not Ca2+, mediates methotrexate‐induced autophagy and apoptosis in spermatocyte cell line , 2020, Basic & clinical pharmacology & toxicology.

[13]  Cheng Lu,et al.  Are gene polymorphisms related to adverse events of methotrexate in patients with rheumatoid arthritis? A retrospective cohort study based on an updated meta-analysis , 2020, Therapeutic advances in chronic disease.

[14]  P. Miossec,et al.  Effects of Methotrexate Alone or Combined With Arthritis-Related Biotherapies in an in vitro Co-culture Model With Immune Cells and Synoviocytes , 2019, Frontiers in Immunology.

[15]  Pei Yang,et al.  Th17 cell pathogenicity and plasticity in rheumatoid arthritis , 2019, Journal of leukocyte biology.

[16]  Chunjie Wu,et al.  Apoptosis Induction of Fibroblast-Like Synoviocytes Is an Important Molecular-Mechanism for Herbal Medicine along with its Active Components in Treating Rheumatoid Arthritis , 2019, Biomolecules.

[17]  C. Caux,et al.  Methotrexate Restores CD73 Expression on Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis Patients and May Contribute to Its Anti-Inflammatory Effect through Ado Production , 2019, Journal of clinical medicine.

[18]  P. Gasque,et al.  Methotrexate an Old Drug with New Tricks , 2019, International journal of molecular sciences.

[19]  L. Wan,et al.  A Novel Chinese Medicine, Xinfeng Capsule, Modulates Proinflammatory Cytokines via Regulating the Toll-Like Receptor 4 (TLR4)/Mitogen-Activated Protein Kinase (MAPK)/Nuclear Kappa B (NF-κB) Signaling Pathway in an Adjuvant Arthritis Rat Model , 2019, Medical science monitor : international medical journal of experimental and clinical research.

[20]  C. Wen,et al.  On Research Progress of Western and Chinese Medicine Treatment on Pre-Rheumatoid Arthritis , 2019, Chinese Journal of Integrative Medicine.

[21]  P. Dutta,et al.  Identification of methotrexate as a heterochromatin-promoting drug , 2019, Scientific Reports.

[22]  H. Yoshikawa,et al.  Drug tolerability and reasons for discontinuation of seven biologics in elderly patients with rheumatoid arthritis -The ANSWER cohort study- , 2019, PloS one.

[23]  K. Yamaoka.  Tofacitinib for the treatment of rheumatoid arthritis: an update , 2019, Expert review of clinical immunology.

[24]  Benjamin Friedman,et al.  Methotrexate mechanism in treatment of rheumatoid arthritis. , 2019, Joint, bone, spine : revue du rhumatisme.

[25]  P. Taylor,et al.  How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?—MTX in the Treat-to-Target Strategy , 2019, Journal of clinical medicine.

[26]  Hsin-Hua Chen,et al.  Association between autophagy and inflammation in patients with rheumatoid arthritis receiving biologic therapy , 2018, Arthritis Research & Therapy.

[27]  M. Rajappa,et al.  Effect of methotrexate monotherapy on T‐cell subsets in the peripheral circulation in psoriasis , 2018, Clinical and experimental dermatology.

[28]  M. Rasool,et al.  uPA/uPAR signaling in rheumatoid arthritis: Shedding light on its mechanism of action , 2018, Pharmacological research.

[29]  K. Yan,et al.  Methotrexate restores the function of peripheral blood regulatory T cells in psoriasis vulgaris via the CD73/AMPK/mTOR pathway , 2018, The British journal of dermatology.

[30]  Wen-peng Zhao,et al.  Combination of 4‐hydroperoxy cyclophosphamide and methotrexate inhibits IL‐6/sIL‐6R‐induced RANKL expression in fibroblast‐like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway , 2018, International immunopharmacology.

[31]  C. Malemud,et al.  The role of the JAK/STAT signal pathway in rheumatoid arthritis , 2018, Therapeutic advances in musculoskeletal disease.

[32]  Eugene Y. Kim,et al.  Immunomodulation of autoimmune arthritis by pro-inflammatory cytokines. , 2017, Cytokine.

[33]  Jing Luo,et al.  Methotrexate, combined with cyclophosphamide attenuates murine collagen induced arthritis by modulating the expression level of Breg and DCs. , 2017, Molecular immunology.

[34]  J. Jacobs,et al.  Identification of differential co-expressed gene networks in early rheumatoid arthritis achieving sustained drug-free remission after treatment with a tocilizumab-based or methotrexate-based strategy , 2017, Arthritis Research & Therapy.

[35]  Hanmei Xu,et al.  Combination Therapy of PEG-HM-3 and Methotrexate Retards Adjuvant-Induced Arthritis , 2017, International journal of molecular sciences.

[36]  M. Šrámek,et al.  Much more than you expected: The non-DHFR-mediated effects of methotrexate. , 2017, Biochimica et biophysica acta. General subjects.

[37]  Tao Liu,et al.  IL-22-producing CD4+T cells in the treatment response of rheumatoid arthritis to combination therapy with methotrexate and leflunomide , 2017, Scientific Reports.

[38]  Yongsheng Yang,et al.  Matrine induces the apoptosis of fibroblast-like synoviocytes derived from rats with collagen-induced arthritis by suppressing the activation of the JAK/STAT signaling pathway , 2016, International journal of molecular medicine.

[39]  J. Isaacs,et al.  Mechanism of action of methotrexate in rheumatoid arthritis, and the search for biomarkers , 2016, Nature Reviews Rheumatology.

[40]  H. Saya,et al.  Methotrexate inhibits osteoclastogenesis by decreasing RANKL-induced calcium influx into osteoclast progenitors , 2016, Journal of Bone and Mineral Metabolism.

[41]  K. Sundqvist,et al.  Methotrexate and its therapeutic antagonists caffeine and theophylline, target a motogenic T‐cell mechanism driven by thrombospondin‐1 (TSP‐1) , 2016, European journal of immunology.

[42]  K. Akashi,et al.  Generation mechanism of RANKL+ effector memory B cells: relevance to the pathogenesis of rheumatoid arthritis , 2016, Arthritis Research & Therapy.

[43]  A. Dopazo,et al.  Methotrexate selectively targets human proinflammatory macrophages through a thymidylate synthase/p53 axis , 2016, Annals of the rheumatic diseases.

[44]  F. Figueiró,et al.  Methotrexate up-regulates ecto-5′-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment , 2016, Purinergic Signalling.

[45]  P. Fishman,et al.  The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis , 2016, Clinical Rheumatology.

[46]  N. Wulffraat,et al.  Methotrexate treatment affects effector but not regulatory T cells in juvenile idiopathic arthritis. , 2015, Rheumatology.

[47]  H. Kaplan,et al.  A2B adenosine receptor activation switches differentiation of bone marrow cells to a CD11c+Gr‐1+ dendritic cell subset that promotes the Th17 response , 2015, Immunity, inflammation and disease.

[48]  Stephen Brown,et al.  Methotrexate Is a JAK/STAT Pathway Inhibitor , 2015, PloS one.

[49]  E. Lubberts,et al.  The role and modulation of CCR6+ Th17 cell populations in rheumatoid arthritis. , 2015, Cytokine.

[50]  M. Dougados,et al.  Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force , 2015, Annals of the rheumatic diseases.

[51]  S. Raychaudhuri,et al.  Role of IL-17 in the pathogenesis of psoriatic arthritis and axial spondyloarthritis , 2015, Clinical Rheumatology.

[52]  A. Cribbs,et al.  Methotrexate Restores Regulatory T Cell Function Through Demethylation of the FoxP3 Upstream Enhancer in Patients With Rheumatoid Arthritis , 2015, Arthritis & rheumatology.

[53]  A. Matuszewska,et al.  Assessment of the Effect of Methotrexate Therapy on Bone Metabolism in Patients with Rheumatoid Arthritis , 2015, Archivum Immunologiae et Therapiae Experimentalis.

[54]  Stephen Brown,et al.  Effect of methotrexate on JAK/STAT pathway activation in myeloproliferative neoplasms , 2015, The Lancet.

[55]  F. Liew,et al.  Low expression of CD39 on regulatory T cells as a biomarker for resistance to methotrexate therapy in rheumatoid arthritis , 2015, Proceedings of the National Academy of Sciences.

[56]  B. Cronstein,et al.  Brief Report: Methotrexate Prevents Wear Particle–Induced Inflammatory Osteolysis in Mice Via Activation of Adenosine A2A Receptor , 2015, Arthritis & rheumatology.

[57]  N. Olsen,et al.  Methotrexate Inhibits NF‐κB Activity Via Long Intergenic (Noncoding) RNA–p21 Induction , 2014, Arthritis & rheumatology.

[58]  M. Barclay,et al.  Assessment of the Relationship Between Methotrexate Polyglutamates in Red Blood Cells and Clinical Response in Patients Commencing Methotrexate for Rheumatoid Arthritis , 2014, Clinical Pharmacokinetics.

[59]  Peter Tugwell,et al.  Methotrexate for treating rheumatoid arthritis. , 2014, The Cochrane database of systematic reviews.

[60]  Xu Wang,et al.  Alternative Expression Pattern of MALT1-A20-NF-κB in Patients with Rheumatoid Arthritis , 2014, Journal of immunology research.

[61]  B. Vásárhelyi,et al.  The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study , 2014, Clinical Rheumatology.

[62]  E. af Klint,et al.  Synovial membrane immunohistology in early-untreated rheumatoid arthritis reveals high expression of catabolic bone markers that is modulated by methotrexate , 2013, Arthritis Research & Therapy.

[63]  Z. Nemeth,et al.  Adenosine augments IL‐10‐induced STAT3 signaling in M2c macrophages , 2013, Journal of leukocyte biology.

[64]  J. Graf,et al.  Methotrexate and a spleen tyrosine kinase inhibitor cooperate to inhibit responses to peripheral blood B cells in rheumatoid arthritis , 2013, Pharmacology research & perspectives.

[65]  Jing Luo,et al.  Combination with Methotrexate and Cyclophosphamide Attenuated Maturation of Dendritic Cells: Inducing Treg Skewing and Th17 Suppression In Vivo , 2013, Clinical & developmental immunology.

[66]  Charles J Malemud,et al.  Intracellular Signaling Pathways in Rheumatoid Arthritis. , 2013, Journal of clinical & cellular immunology.

[67]  M. Schrappe,et al.  Germline genetic variations in methotrexate candidate genes are associated with pharmacokinetics, toxicity, and outcome in childhood acute lymphoblastic leukemia. , 2013, Blood.

[68]  Yao Yao,et al.  Combination of MTX and LEF attenuates inflammatory bone erosion by down-regulation of receptor activator of NF-kB ligand and interleukin-17 in type II collagen-induced arthritis rats , 2013, Rheumatology International.

[69]  B. Cronstein,et al.  Regulation of Inflammation by Adenosine , 2013, Front. Immunol..

[70]  N. Olsen,et al.  Methotrexate increases expression of cell cycle checkpoint genes via JNK activation. , 2012, Arthritis and rheumatism.

[71]  R. Mader,et al.  A randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritis. , 2012, Clinical therapeutics.

[72]  Jin-Young Park,et al.  Interleukin-22 promotes osteoclastogenesis in rheumatoid arthritis through induction of RANKL in human synovial fibroblasts. , 2012, Arthritis and rheumatism.

[73]  T. Curiel,et al.  Targeting regulatory T cells , 2012, Targeted Oncology.

[74]  K. Varani,et al.  A2A and A3 adenosine receptor expression in rheumatoid arthritis: upregulation, inverse correlation with disease activity score and suppression of inflammatory cytokine and metalloproteinase release , 2011, Arthritis research & therapy.

[75]  M. Ehrenstein,et al.  Regulatory T‐cells in systemic lupus erythematosus and rheumatoid arthritis , 2011, FEBS letters.

[76]  Jeffrey M. Wilson,et al.  The A2B Adenosine Receptor Promotes Th17 Differentiation via Stimulation of Dendritic Cell IL-6 , 2011, The Journal of Immunology.

[77]  Cong-hua Wang,et al.  Combined Treatment of Etanercept and MTX Reverses Th1/Th2, Th17/Treg Imbalance in Patients with Rheumatoid Arthritis , 2011, Journal of Clinical Immunology.

[78]  F. Cantatore,et al.  Osteoblast physiology in normal and pathological conditions , 2011, Cell and Tissue Research.

[79]  Yuan Fang,et al.  Therapeutic efficacy of experimental rheumatoid arthritis with low-dose methotrexate by increasing partially CD4+CD25+ Treg cells and inducing Th1 to Th2 shift in both cells and cytokines. , 2010, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[80]  E. Vizi,et al.  Adenosine A2A receptor activation protects CD4+ T lymphocytes against activation‐induced cell death , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[81]  B. Fredholm,et al.  Adenosine A1 receptors (A1Rs) play a critical role in osteoclast formation and function , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[82]  H. Takayanagi.  New immune connections in osteoclast formation , 2010, Annals of the New York Academy of Sciences.

[83]  B. Cronstein,et al.  Methotrexate—how does it really work? , 2010, Nature Reviews Rheumatology.

[84]  G. Firestein,et al.  Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritis , 2010, Immunological reviews.

[85]  C. Malemud,et al.  Recent advances in neutralizing the IL-6 pathway in arthritis , 2009, Open access rheumatology : research and reviews.

[86]  S. Teitelbaum,et al.  Osteoclasts and Arthritis , 2009, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[87]  M. Hashizume,et al.  IL-6 trans-signalling directly induces RANKL on fibroblast-like synovial cells and is involved in RANKL induction by TNF-alpha and IL-17. , 2008, Rheumatology.

[88]  D. Aeschlimann,et al.  IL‐23 promotes osteoclast formation by up‐regulation of receptor activator of NF‐κB (RANK) expression in myeloid precursor cells , 2008, European journal of immunology.

[89]  M. Ehrenfeld,et al.  Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients. , 2008, Clinical and experimental rheumatology.

[90]  G. Firestein,et al.  The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[91]  Y. Assaraf.  The role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis. , 2006, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[92]  J. Zwerina,et al.  Mechanisms of Disease: the link between RANKL and arthritic bone disease , 2005, Nature Clinical Practice Rheumatology.

[93]  S. Yao,et al.  The equilibrative nucleoside transporter family, SLC29 , 2004, Pflügers Archiv.

[94]  R. Hughes,et al.  Folate supplementation and methotrexate treatment in rheumatoid arthritis: a review. , 2003, Rheumatology.

[95]  M. Sitkovsky,et al.  Adenosine and adenosine receptors in the pathogenesis and treatment of rheumatic diseases , 2017, Nature Reviews Rheumatology.

[96]  N. Olsen,et al.  Methotrexate-mediated inhibition of nuclear factor κB activation by distinct pathways in T cells and fibroblast-like synoviocytes. , 2015, Rheumatology.

[97]  Yao Yao,et al.  A combination of sinomenine and methotrexate reduces joint damage of collagen induced arthritis in rats by modulating osteoclast-related cytokines. , 2014, International immunopharmacology.

[98]  P. Kostenuik,et al.  Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. , 2008, Endocrine reviews.